Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis.

about

Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine

P2860

Q57107703-BB012A5F-F913-4B20-A9A1-693332F117D9

P2860

Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis.

Item

http://www.wikidata.org/entity/Q55262610

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Prostate specific antigen (PSA ...... atic review and meta-analysis.

@en

type

Item

label

Prostate specific antigen (PSA ...... atic review and meta-analysis.

@en

prefLabel

Prostate specific antigen (PSA ...... atic review and meta-analysis.

@en

P1476

Prostate specific antigen (PSA ...... matic review and meta-analysis

@en

P2093

Chaidir Arif Mochtar

http://www.w3.org/2001/XMLSchema#string

Rainy Umbas

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

Predictors of survival outcomes in native sub Saharan black men newly diagnosed with metastatic prostate cancer.

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer

The use of early postoperative prostate-specific antigen to stratify risk in patients with positive surgical margins after radical prostatectomy.

Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels

Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.

The utility of prostate-specific antigen in the management of advanced prostate cancer.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer.

P304

246

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.12688/F1000RESEARCH.14026.1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Agus Rizal Ardy Hariandy Hamid

Andika Afriansyah

P577

2018-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29904592

http://www.w3.org/2001/XMLSchema#string

P932

5964636

http://www.w3.org/2001/XMLSchema#string

Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis.

about

P2860

P2860

Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932